Perspectives on Enquiry & Evidence
Reflections on the RCT DUPLICATE Study and Increasing Confidence in Real-World Evidence
Randomized clinical trials (RCTs) have long been considered the gold standard for assessing the efficacy of medical treatments, but real-world evidence (RWE) is often more representative of routine clinical care. The RCT DUPLICATE study makes great strides in comparing the two, but the study has its limitations: notably, the lack of quantitative bias analysis.
Inside an Oncology Statistician's Toolkit
Case Study: BLRM for Phase 1/2a Oncology Study
An Introduction to BLRM
How does the T-Statistic stack up for finding MTD?
Webinar Replay: Single and Double Agent Dose Escalation Designs
Bayesian Dose Escalation Designs for Late Onset Toxicity
A Bayesian Industry Approach to Phase I Combination Trials in Oncology
Adaptive Designs for Evidence Based Oncology: Insights from the Experts
Subscribe to our weekly newsletter
By submitting you agree to Cytel’s Privacy Notice